FIGURE

Fig. 7

ID

ZDB-FIG-211009-30

Publication

He et al., 2021 - Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

Other Figures

All Figure Page

Back to All Figure Page

Fig. 7

Venetoclax and S63845 synergize with sirolimus to induce apoptosis in human <italic>NF1/PTEN</italic>-deficient melanoma cells.

a Western blots for NF1 and PTEN in a panel of human melanoma cell lines. HEK293 and Jurkart cells were included as positive and negative controls. The levels of total ERK1/2 expression serve as the loading control. b Relative cell viability of WM-3246 cells (Cell Titer Glo assay) upon treatment with sirolimus, venetoclax, or S63845 for 6 days. Mean ± s.d. values. c Relative cell viability of WM-3246 cells (Cell Titer Glo assay) upon treatment with the combination of sirolimus, venetoclax, and S63845 for 6 days. Mean ± s.d. values. d WM-3246 cell growth kinetics after treatment with the combination of sirolimus, venetoclax, and S63845 (for doses see panel c). Mean ± s.d. values. e Synergistic effects of venetoclax and S63845 on suppression of sirolimus-sensitized WM-3246 cells were analyzed by isobologram analysis. f Western blots for BCL2, BCLXL, and MCL1 in WM-3246 cells treated with venetoclax or S63845 for 24 h. g Western blots for cleaved caspase-3 in WM-3246 cells treated with the combination of sirolimus, venetoclax, and S63845.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene